Roberta R. Alfieri

Parma, Italy

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 117 publications

The role of circulating tumor DNA (ctDNA) to detect minimal residual disease in locally advanced gastroesophageal carcinoma: the BUTTERFLY study.

The role of circulating tumor DNA (ctDNA) to detect minimal residual disease in locally advanced gastroesophageal carcinoma: the BUTTERFLY study.

Journal: ESMO gastrointestinal oncology

Published: September 03, 2026

Correction: Enhancement of the anti-tumor activity of FGFR1 inhibition in squamous cell lung cancer by targeting downstream signaling involved in glucose metabolism.

Correction: Enhancement of the anti-tumor activity of FGFR1 inhibition in squamous cell lung cancer by targeting downstream signaling involved in glucose metabolism.

Journal: Oncotarget

Published: April 09, 2026

Correction: Effects of sorafenib on energy metabolism in breast cancer cells: role of AMPK-mTORC1 signaling.

Correction: Effects of sorafenib on energy metabolism in breast cancer cells: role of AMPK-mTORC1 signaling.

Journal: Breast cancer research and treatment

Published: January 24, 2026

Targeting HGF/MET and CXCL1/CXCR2 axes bypasses resistance to KRASG12C inhibitors in NSCLC.

Targeting HGF/MET and CXCL1/CXCR2 axes bypasses resistance to KRASG12C inhibitors in NSCLC.

Journal: Lung cancer (Amsterdam, Netherlands)

Published: November 13, 2025

Prognostic impact of pathological complete response and response-adapted outcomes in patients with gastroesophageal adenocarcinoma treated with neoadjuvant or perioperative treatments: a multicentric cohort study.

Prognostic impact of pathological complete response and response-adapted outcomes in patients with gastroesophageal adenocarcinoma treated with neoadjuvant or perioperative treatments: a multicentric cohort study.

Journal: ESMO open

Published: September 13, 2025

Correction: The anti-tumor efficacy of CDK4/6 Inhibition is enhanced by the combination with PI3K/AKT/mTOR inhibitors through impairment of glucose metabolism in TNBC cells.

Correction: The anti-tumor efficacy of CDK4/6 Inhibition is enhanced by the combination with PI3K/AKT/mTOR inhibitors through impairment of glucose metabolism in TNBC cells.

Journal: Journal of experimental & clinical cancer research : CR

Published: April 15, 2025

Correction: Tumor Microenvironment Landscapes Supporting EGFR-mutant NSCLC Are Modulated at the Single-cell Interaction Level by Unesbulin Treatment.

Correction: Tumor Microenvironment Landscapes Supporting EGFR-mutant NSCLC Are Modulated at the Single-cell Interaction Level by Unesbulin Treatment.

Journal: Cancer research communications

Published: April 08, 2025

Correction: Cavazzoni et al. Pemetrexed Enhances Membrane PD-L1 Expression and Potentiates T Cell-Mediated Cytotoxicity by Anti-PD-L1 Antibody Therapy in Non-Small-Cell Lung Cancer. Cancers 2020, 12, 666.

Correction: Cavazzoni et al. Pemetrexed Enhances Membrane PD-L1 Expression and Potentiates T Cell-Mediated Cytotoxicity by Anti-PD-L1 Antibody Therapy in Non-Small-Cell Lung Cancer. Cancers 2020, 12, 666.

Journal: Cancers

Published: March 04, 2025

Isolation and characterization of extracellular vesicles from EGFR mutated lung cancer cells.

Isolation and characterization of extracellular vesicles from EGFR mutated lung cancer cells.

Journal: Clinical and experimental medicine

Published: January 10, 2025

Corrigendum to "Mesenchymal stromal cells loaded with Paclitaxel (PacliMES) a potential new therapeutic approach on mesothelioma" [Biochem. Pharmacol. 214 (2023) 115678].

Corrigendum to "Mesenchymal stromal cells loaded with Paclitaxel (PacliMES) a potential new therapeutic approach on mesothelioma" [Biochem. Pharmacol. 214 (2023) 115678].

Journal: Biochemical pharmacology

Published: November 29, 2024

Corrigendum: CDK4/6 inhibitors improve the anti-tumor efficacy of lenvatinib in hepatocarcinoma cells.

Corrigendum: CDK4/6 inhibitors improve the anti-tumor efficacy of lenvatinib in hepatocarcinoma cells.

Journal: Frontiers in oncology

Published: November 21, 2024

Mechanisms of hematopoietic clonal dominance in VEXAS syndrome.

Mechanisms of hematopoietic clonal dominance in VEXAS syndrome.

Journal: Nature medicine

Published: July 08, 2024

Showing 1-12 of 117

Last Updated: 09/26/2026